Can Metabolic Changes Be Targeted for Cancer Therapy?
Targeting the altered metabolic pathways in cancer cells presents a promising therapeutic strategy. Inhibitors of glycolysis, such as 2-deoxy-D-glucose, and inhibitors of glutaminase, an enzyme crucial for glutamine metabolism, are being explored in clinical trials. However, the challenge lies in selectively targeting cancer cells without affecting normal cells.
